SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Giuseppe Cariti, Alessia Ciancio, Antonina Smedile, Silvia Strona, Giulia Troshina, Mario Rizzetto, Giovanni Di Perri, Antonio D’Avolio, ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy, Biomedicine & Pharmacotherapy, 2015, 69, 63

    CrossRef

  2. 2
    Nicola F. Fletcher, Rupesh Sutaria, Juandy Jo, Amy Barnes, Miroslava Blahova, Luke W. Meredith, Francois-Loic Cosset, Stuart M. Curbishley, David H. Adams, Antonio Bertoletti, Jane A. McKeating, Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner, Hepatology, 2014, 59, 4
  3. 3
    J. Kyle Weston, Jack Uetrecht, Activation of Inflammasomes by Agents Causing Idiosyncratic Skin Reactions: A Possible Biomarker, Chemical Research in Toxicology, 2014, 27, 6, 949

    CrossRef

  4. 4
    Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, Maxwell D. Cummings, Oliver Lenz, Pierre Raboisson, Kenny Simmen, Sandrine Vendeville, Herman de Kock, Magnus Nilsson, Andras Horvath, Ronald Kalmeijer, Guy de la Rosa, Maria Beumont-Mauviel, Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor, Journal of Medicinal Chemistry, 2014, 57, 5, 1673

    CrossRef

  5. 5
    Pierre L. Beaulieu, Paul C. Anderson, Richard Bethell, Michael Bös, Yves Bousquet, Christian Brochu, Michael G. Cordingley, Gulrez Fazal, Michel Garneau, James R. Gillard, Stephen Kawai, Martin Marquis, Ginette McKercher, Marc-André Poupart, Timothy Stammers, Bounkham Thavonekham, Dominik Wernic, Jianmin Duan, George Kukolj, Discovery of BI 207524, an Indole Diamide NS5B Thumb Pocket 1 Inhibitor with Improved Potency for the Potential Treatment of Chronic Hepatitis C Virus Infection, Journal of Medicinal Chemistry, 2014, 57, 23, 10130

    CrossRef

  6. 6
    Oliver Hucke, René Coulombe, Pierre Bonneau, Mégan Bertrand-Laperle, Christian Brochu, James Gillard, Marc-André Joly, Serge Landry, Olivier Lepage, Montse Llinàs-Brunet, Marc Pesant, Martin Poirier, Maude Poirier, Ginette McKercher, Martin Marquis, George Kukolj, Pierre L. Beaulieu, Timothy A. Stammers, Molecular Dynamics Simulations and Structure-Based Rational Design Lead to Allosteric HCV NS5B Polymerase Thumb Pocket 2 Inhibitor with Picomolar Cellular Replicon Potency, Journal of Medicinal Chemistry, 2014, 57, 5, 1932

    CrossRef

  7. 7
    Il Hak Bae, Jin Kyu Choi, Chieyeon Chough, Sun Ju Keum, Heesun Kim, Sung Key Jang, B. Moon Kim, Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core, ACS Medicinal Chemistry Letters, 2014, 5, 3, 255

    CrossRef

  8. 8
    Yasuhiro Kamo, Tatsuki Ichikawa, Hisamitsu Miyaaki, Shinjirou Uchida, Tohei Yamaguchi, Hidetaka Shibata, Takuya Honda, Naota Taura, Hajime Isomoto, Fuminao Takeshima, Kazuhiko Nakao, Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy, Hepatology Research, 2014, 44, 14
  9. 9
    Tarik Asselah, Sofosbuvir for the treatment of hepatitis C virus, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 121

    CrossRef

  10. 10
    Y. Karino, I. Ozeki, S. Hige, M. Kimura, T. Arakawa, T. Nakajima, Y. Kuwata, T. Sato, T. Ohmura, J. Toyota, Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2014, 21, 5
  11. 11
    Tasuku Hara, Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Hiromitsu Kumada, A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C, Journal of Medical Virology, 2013, 85, 10
  12. 12
    Sabar Pambudi, Norihito Kawashita, Supranee Phanthanawiboon, Magot Diata Omokoko, Promsin Masrinoul, Akifumi Yamashita, Kriengsak Limkittikul, Teruo Yasunaga, Tatsuya Takagi, Kazuyoshi Ikuta, Takeshi Kurosu, A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication, Biochemical and Biophysical Research Communications, 2013, 440, 3, 393

    CrossRef

  13. 13
    Pierre L. Beaulieu, René Coulombe, James Gillard, Christian Brochu, Jianmin Duan, Michel Garneau, Eric Jolicoeur, Peter Kuhn, Marc-André Poupart, Jean Rancourt, Timothy A. Stammers, Bounkham Thavonekham, George Kukolj, AllostericN-acetamide-indole-6-carboxylic acid thumb pocket 1 inhibitors of hepatitis C virus NS5B polymerase — Acylsulfonamides and acylsulfamides as carboxylic acid replacements, Canadian Journal of Chemistry, 2013, 91, 1, 66

    CrossRef

  14. 14
    Elamin H. Elbasha, Jagpreet Chhatwal, Shannon A. Ferrante, Antoine C. El Khoury, Pedro A. Laires, Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal, Applied Health Economics and Health Policy, 2013, 11, 1, 65

    CrossRef

  15. 15
    Guangming Chen, Hongyu Ren, Anthony Turpoff, Alexander Arefolov, Richard Wilde, James Takasugi, Atiyya Khan, Neil Almstead, Zhengxian Gu, Takashi Komatsu, Connie Freund, Jamie Breslin, Joseph Colacino, Jean Hedrick, Marla Weetall, Gary M. Karp, Discovery of N-(4′-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 13, 3942

    CrossRef

  16. 16
    Waleed Hassan AlMalki, HCV infection: an enigma, recent advances and new paradigms for its treatment, Future Virology, 2013, 8, 4, 381

    CrossRef

  17. 17
    Aaron Cohn, Andrew Aronsohn, HCV Therapy: Treat now or wait?, Current Hepatitis Reports, 2013, 12, 1, 7

    CrossRef

  18. 18
    H. J. Harris, C. Clerte, M. J. Farquhar, M. Goodall, K. Hu, P. Rassam, P. Dosset, G. K. Wilson, P. Balfe, S. C. IJzendoorn, P. E. Milhiet, J. A. McKeating, Hepatoma polarization limits CD81 and hepatitis C virus dynamics, Cellular Microbiology, 2013, 15, 3
  19. 19
    Michel Rotily, Alexandre Vainchtock, Baptiste Jouaneton, Claire Wartelle-Bladou, Armand Abergel, How did chronic hepatitis C impact costs related to hospital health care in France in 2009?, Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 4, 365

    CrossRef

  20. You have free access to this content20
    Angeli Chopra, Patricia L. Klein, Thia Drinnan, Samuel S. Lee, How to optimize HCV therapy in genotype 1 patients: management of side-effects, Liver International, 2013, 33,
  21. 21
    D. N. Martin, S. L. Uprichard, Identification of transferrin receptor 1 as a hepatitis C virus entry factor, Proceedings of the National Academy of Sciences, 2013, 110, 26, 10777

    CrossRef

  22. 22
    Hiroshi Abe, Yuta Aida, Haruya Ishiguro, Kai Yoshizawa, Nobuyoshi Seki, Tamihiro Miyazaki, Munenori Itagaki, Satoshi Sutoh, Makiko Ika, Keizo Kato, Noritomo Shimada, Akihito Tsubota, Yoshio Aizawa, New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection, Journal of Medical Virology, 2013, 85, 9
  23. 23
    Pierre L. Beaulieu, René Coulombe, Jianmin Duan, Gulrez Fazal, Cédrickx Godbout, Oliver Hucke, Araz Jakalian, Marc-André Joly, Olivier Lepage, Montse Llinàs-Brunet, Julie Naud, Martin Poirier, Nathalie Rioux, Bounkham Thavonekham, George Kukolj, Timothy A. Stammers, Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 14, 4132

    CrossRef

  24. 24
    Thibaut Vausselin, Noémie Calland, Sandrine Belouzard, Véronique Descamps, Florian Douam, François Helle, Catherine François, Dimitri Lavillette, Gilles Duverlie, Ahmed Wahid, Lucie Fénéant, Laurence Cocquerel, Yann Guérardel, Czeslaw Wychowski, Christophe Biot, Jean Dubuisson, The antimalarial ferroquine is an inhibitor of hepatitis C virus, Hepatology, 2013, 58, 1
  25. 25
    L Baccaglini, K Thongprasom, M Carrozzo, M Bigby, Urban legends series: lichen planus, Oral Diseases, 2013, 19, 2
  26. 26
    Noémie Calland, Anna Albecka, Sandrine Belouzard, Czeslaw Wychowski, Gilles Duverlie, Véronique Descamps, Didier Hober, Jean Dubuisson, Yves Rouillé, Karin Séron, (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry, Hepatology, 2012, 55, 3
  27. 27
    Maxime Touzot, Vassili Soumelis, Tarik Asselah, A dive into the complexity of type I interferon antiviral functions, Journal of Hepatology, 2012, 56, 3, 726

    CrossRef

  28. 28
    Christophe Hézode, Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice, Liver International, 2012, 32,
  29. 29
    Mei H. Chang, Lori A. Gordon, Horatio B. Fung, Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C, Clinical Therapeutics, 2012, 34, 10, 2021

    CrossRef

  30. 30
    Tarik Asselah, Patrick Marcellin, Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow, Liver International, 2012, 32,
  31. 31
    Pierre L. Beaulieu, Michael Bös, Michael G. Cordingley, Catherine Chabot, Gulrez Fazal, Michel Garneau, James R. Gillard, Eric Jolicoeur, Steven LaPlante, Ginette McKercher, Martin Poirier, Marc-André Poupart, Youla S. Tsantrizos, Jianmin Duan, George Kukolj, Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV), Journal of Medicinal Chemistry, 2012, 55, 17, 7650

    CrossRef

  32. 32
    Philippe Halfon, Christoph Sarrazin, Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?, Liver International, 2012, 32,
  33. 33
    Tommaso Maria Manzia, Roberta Angelico, Luca Toti, Quirino Lai, Paolo Ciano, Mario Angelico, Giuseppe Tisone, Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation, Expert Review of Clinical Immunology, 2012, 8, 7, 635

    CrossRef

  34. 34
    Bruno Roche, Didier Samuel, Hepatitis C virus treatment pre- and post-liver transplantation, Liver International, 2012, 32,
  35. 35
    Tarik Asselah, Simon De Muynck, Philippe Broët, Julien Masliah-Planchon, Maud Blanluet, Ivan Bièche, Martine Lapalus, Michelle Martinot-Peignoux, Olivier Lada, Emilie Estrabaud, Qian Zhang, Ahmed El Ray, Dominique Vidaud, Marie-Pierre Ripault, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Patrick Marcellin, IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C, Journal of Hepatology, 2012, 56, 3, 527

    CrossRef

  36. 36
    Atsuya Yamashita, Kazi Abdus Salam, Atsushi Furuta, Yasuyoshi Matsuda, Osamu Fujita, Hidenori Tani, Yoshihisa Fujita, Yuusuke Fujimoto, Masanori Ikeda, Nobuyuki Kato, Naoya Sakamoto, Shinya Maekawa, Nobuyuki Enomoto, Masamichi Nakakoshi, Masayoshi Tsubuki, Yuji Sekiguchi, Satoshi Tsuneda, Nobuyoshi Akimitsu, Naohiro Noda, Junichi Tanaka, Kohji Moriishi, Inhibition of Hepatitis C Virus Replication and Viral Helicase by Ethyl Acetate Extract of the Marine Feather Star Alloeocomatella polycladia, Marine Drugs, 2012, 10, 12, 744

    CrossRef

  37. 37
    Annett Kunze, Jörg Huwyler, Gian Camenisch, Heike Gutmann, Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters, Biochemical Pharmacology, 2012, 84, 8, 1096

    CrossRef

  38. 38
    Nobuhisa Akamatsu, Yasuhiko Sugawara, Liver Transplantation and Hepatitis C, International Journal of Hepatology, 2012, 2012, 1

    CrossRef

  39. 39
    Sandra Bühler, Ralf Bartenschlager, New targets for antiviral therapy of chronic hepatitis C, Liver International, 2012, 32,
  40. 40
    Dahlene N. Fusco, Raymond T. Chung, Novel Therapies for Hepatitis C: Insights from the Structure of the Virus, Annual Review of Medicine, 2012, 63, 1, 373

    CrossRef

  41. 41
    Sylvie Larrat, Cécile Bourdon, Monique Baccard, Cécile Garnaud, Sophie Mathieu, Jean-Louis Quesada, Anne Signori-Schmuck, Raphaele Germi, Myriam Blanc, Pascale Leclercq, Marie-Noelle Hilleret, Vincent Leroy, Jean-Pierre Zarski, Patrice Morand, Performance of an antigen–antibody combined assay for hepatitis C virus testing without venipuncture, Journal of Clinical Virology, 2012, 55, 3, 220

    CrossRef

  42. 42
    Jeni Page, Recent Developments in the Treatment of Chronic Hepatitis C, The Journal for Nurse Practitioners, 2012, 8, 3, 225

    CrossRef

  43. 43
    Syed-Mohammad Jafri, Stuart C. Gordon, Second Generation Protease Inhibitors and Nucleotide Inhibitors, Current Hepatitis Reports, 2012, 11, 3, 172

    CrossRef

  44. 44
    Junxing Shi, Longhu Zhou, Franck Amblard, Drew R. Bobeck, Hongwang Zhang, Peng Liu, Lavanya Bondada, Tamara R. McBrayer, Phillip M. Tharnish, Tony Whitaker, Steven J. Coats, Raymond F. Schinazi, Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 10, 3488

    CrossRef

  45. 45
    Hiromitsu Kumada, Joji Toyota, Takeshi Okanoue, Kazuaki Chayama, Hirohito Tsubouchi, Norio Hayashi, Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan, Journal of Hepatology, 2012, 56, 1, 78

    CrossRef

  46. 46
    G. Esmat, M. El Raziky, M. El Kassas, M. Hassany, M.E. Gamil, The future for the treatment of genotype 4 chronic hepatitis C, Liver International, 2012, 32,
  47. 47
    Virginia Clark, David R. Nelson, The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C, Liver International, 2012, 32,
  48. 48
    G. Esmat, M. Raziky, M. El-Kassas, M. Hassany, M. E. Gamil, Treatment of Chronic HCV Genotype 4 Infection, Current Hepatitis Reports, 2012, 11, 4, 250

    CrossRef

  49. 49
    Peter Ferenci, Treatment of chronic hepatitis C – are interferons really necessary?, Liver International, 2012, 32,
  50. 50
    Shiv K. Sarin, Chandan K. N. Kumar, Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies, Liver International, 2012, 32,
  51. 51
    Graham R. Foster, Lawrence D. Serfaty, Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: ‘Lead-in or no lead-in’?, Liver International, 2012, 32,
  52. 52
    Bruce R. Bacon, Omer Khalid, Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders, Liver International, 2012, 32,
  53. 53
    Alessandra Mangia, Leonardo Mottola, What's new in HCV genotype 2 treatment, Liver International, 2012, 32,
  54. 54
    Marion G. Peters, Monika Sarkar, Sande's HIV/AIDS Medicine, 2012,

    CrossRef

  55. 55
    Tarik Asselah, A sprint to increase response to HCV treatment: Expectancies but caution, Journal of Hepatology, 2011, 55, 5, 1154

    CrossRef

  56. 56
    Emilie Estrabaud, Simon De Muynck, Tarik Asselah, Activation of unfolded protein response and autophagy during HCV infection modulates innate immune response, Journal of Hepatology, 2011, 55, 5, 1150

    CrossRef

  57. 57
    S. Deuffic-Burban, E. Delarocque-Astagneau, D. Abiteboul, E. Bouvet, Y. Yazdanpanah, Blood-borne viruses in health care workers: Prevention and management, Journal of Clinical Virology, 2011, 52, 1, 4

    CrossRef

  58. 58
    Marc Bourlière, Asma Khaloun, Claire Wartelle-Bladou, Valérie Oules, Isabelle Portal, Souad Benali, Xavier Adhoute, Paul Castellani, Chronic hepatitis C: Treatments of the future, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S84

    CrossRef

  59. 59
    P. Burra, E. De Martin, Infections and Organ Transplantation: New Challenges for Prevention and Treatment of Hepatitis C Virus, Transplantation Proceedings, 2011, 43, 6, 2455

    CrossRef

  60. 60
    Stephane Chevaliez, Tarik Asselah, Mechanisms of non-response to antiviral treatment in chronic hepatitis C, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S31

    CrossRef

  61. 61
    Christophe Hézode, Oral combination therapy: Future hepatitis C virus treatment?, Journal of Hepatology, 2011, 55, 4, 933

    CrossRef

  62. 62
    Tarik Asselah, Realize the advance in HCV treatment, but remain cautious, Journal of Hepatology, 2011, 55, 6, 1457

    CrossRef

  63. 63
    Sandra Ciesek, Thomas von Hahn, Michael P. Manns, Second-wave Protease Inhibitors: Choosing an Heir, Clinics in Liver Disease, 2011, 15, 3, 597

    CrossRef

  64. 64
    Radha K Dhiman, The Green Tea Polyphenol, Epigallocatechin-3-Gallate (EGCG)—One Step Forward in Antiviral Therapy Against Hepatitis C Virus, Journal of Clinical and Experimental Hepatology, 2011, 1, 3, 159

    CrossRef

  65. 65
    Marcello Persico, Savino Bruno, Andrea Costantino, Marta Mazza, Piero Luigi Almasio, The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection, International Journal of Hepatology, 2011, 2011, 1

    CrossRef